Liraglutide and renal outcomes in type 2 diabetes

Mann, Johannes F.E., Ørsted, David D., Brown-Frandsen, Kirstine, Marso, Steven P., Poulter, Neil R., Rasmussen, Søren, Tornøe, Karen, Zinman, Bernard, Buse, John B., and LEADER Investigators, (2017) Liraglutide and renal outcomes in type 2 diabetes. New England Journal of Medicine, 377 (9). pp. 839-848.

[img]
Preview
PDF - Published Version
Download (450kB) | Preview
View at Publisher Website: http://dx.doi.org/10.1056/NEJMoa1616011
 
291


Abstract

Background: In a randomized, controlled trial that compared liraglutide, a glucagon-like peptide 1 analogue, with placebo in patients with type 2 diabetes and high cardiovascular risk who were receiving usual care, we found that liraglutide resulted in lower risks of the primary end point (nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes) and death. However, the long-term effects of liraglutide on renal outcomes in patients with type 2 diabetes are unknown.

Methods: We report the prespecified secondary renal outcomes of that randomized, controlled trial in which patients were assigned to receive liraglutide or placebo. The secondary renal outcome was a composite of new-onset persistent macroalbuminuria, persistent doubling of the serum creatinine level, end-stage renal disease, or death due to renal disease. The risk of renal outcomes was determined with the use of time-to-event analyses with an intention-to-treat approach. Changes in the estimated glomerular filtration rate and albuminuria were also analyzed.

Results: A total of 9340 patients underwent randomization, and the median follow-up of the patients was 3.84 years. The renal outcome occurred in fewer participants in the liraglutide group than in the placebo group (268 of 4668 patients vs. 337 of 4672; hazard ratio, 0.78; 95% confidence interval [CI], 0.67 to 0.92; P=0.003). This result was driven primarily by the new onset of persistent macroalbuminuria, which occurred in fewer participants in the liraglutide group than in the placebo group (161 vs. 215 patients; hazard ratio, 0.74; 95% CI, 0.60 to 0.91; P=0.004). The rates of renal adverse events were similar in the liraglutide group and the placebo group (15.1 events and 16.5 events per 1000 patient-years), including the rate of acute kidney injury (7.1 and 6.2 events per 1000 patient-years, respectively).

Conclusion: This prespecified secondary analysis shows that, when added to usual care, liraglutide resulted in lower rates of the development and progression of diabetic kidney disease than placebo.

Item ID: 51385
Item Type: Article (Research - C1)
ISSN: 1533-4406
Funders: Novo Nordisk Foundation (NNF), National Institutes of Health (NIH)
Projects and Grants: NIH NTC01179048
Date Deposited: 16 Nov 2017 23:49
FoR Codes: 11 MEDICAL AND HEALTH SCIENCES > 1103 Clinical Sciences > 110306 Endocrinology @ 100%
SEO Codes: 92 HEALTH > 9201 Clinical Health (Organs, Diseases and Abnormal Conditions) > 920104 Diabetes @ 100%
Downloads: Total: 291
Last 12 Months: 74
More Statistics

Actions (Repository Staff Only)

Item Control Page Item Control Page